Dendritic cells (DCs) bridge the gap between innate and adaptive immunity and are regarded as orchestrators of  immunological responses. This makes them an interesting target for immunotherapies. Within the DC4Balance consortium, I am focusing on the development of DC-modulating vaccines for allergen immunotherapy. The goal of our research is to target DCs in vivo to reporgram the allergy-associated Th2 response. Therefore, we aim to compose a nanoparticle-based drug delivery system, containing the respective allergen in combination with an immunomodulative adjuvant to induce an antigen-specific regulatory T cell response.